Recent Advances in Immunotherapeutic Methods for the Treatment of Infectious Diseases

Harada Kevin^*
*Correspondence: Harada Kevin, Department of Infectious Diseases, University of Bristol, Beacon House, Queens Rd, Bristol BS8 1QU, UK, Email:

Introduction

Because they cause considerable morbidity and mortality worldwide, infectious illnesses continue to be a key global health problem. The management of infectious disorders has benefited greatly by the use of conventional therapies such antibiotics and antiviral medications. The increase of drug resistance and the shortcomings of conventional treatments, however, have prompted the creation of novel immunotherapeutic strategies. Significant advances in using the immune system's capacity to fight infectious illnesses have been made in recent years. The treatment of infectious illnesses may be impacted by certain recent developments in immunotherapeutic methods, which are explored in this article.

To offer instant protection against infections, passive immunization uses the delivery of pre-formed antibodies. This method is especially helpful for people with weakened immune systems or in emergency situations. Plasma from patients who have recovered from an illness is called convalescent plasma and it has a high level of antibodies that are unique to the pathogen. It has been used effectively to treat illnesses like COVID-19, the flu and Ebola. Another type of passive vaccination that may be made to target certain infections is monoclonal antibodies, which are manufactured in laboratories [1]. In active immunization, the immune system is stimulated to produce a protective immunological response against a specific disease. The most popular type of active immunization is vaccination. By training the immune system to detect and respond to certain infections, traditional vaccinations have proved very successful in preventing infectious illnesses. The goal of ongoing research is to create new vaccines or enhance current ones. New vaccination platforms are being developed and adjuvants are being used to boost immune responses.

Description

While vaccinations are often used to prevent disease, therapeutic vaccines are made to treat those who have already contracted the disease. These vaccinations are designed to elicit an immune response that targets and destroys the pathogen precisely. Human Papillomavirus (HPV), hepatitis B and HIV are just a few of the persistent viral illnesses that can be treated using therapeutic vaccinations. They may reduce viral loads, delay the spread of the illness and enhance immunological control of the infection. To improve the immune response against infections, a patient's own T cells are modified and reinfused during T-cell therapy [2]. Chimeric Antigen Receptor (CAR) T-cell therapy is one famous example, since it has proven to be remarkably effective in the treatment of several malignancies. Also being investigated is CAR T-cell therapy for infectious disorders, notably viral infections. CAR T cells are a very effective kind of immunotherapy that target and destroy infected cells by genetically altering T cells to express receptors specific to viral antigens.

In order to modify the immune system and improve its capacity to fight infections, cytokine treatment includes the injection of certain cytokines. For instance, the use of interferon therapy to treat hepatitis B and C infections has been shown to increase antiviral responses and decrease viral replication. In HIV infection, interleukin-2 (IL-2) treatment has been investigated to increase immune cell production and improve immunological control of the virus. The potential of the immune system to identify and combat cancer cells has been unleashed by immune checkpoint inhibitors, revolutionizing cancer therapy [3]. These inhibitors stop the proteins that control immunological checkpoints, enabling immune cells to fight cancer more effectively.

Monoclonal antibodies (mAbs) are manufactured in a lab and are antibodies with a specific pathogen or immune system component in mind. Recent innovations have resulted in the creation of mAbs that are very effective against different infectious pathogens. For instance, in clinical studies, mAbs that target the Ebola virus have demonstrated encouraging benefits, lowering fatality rates and enhancing patient outcomes. Similar to RSV, Clostridium difficile infection and other bacterial and viral diseases, mAbs have also been created [4]. These mAbs can offer instantaneous immunity and support the body's inbuilt defenses against infections. Immune cells are transferred as part of adoptive cell treatments in order to strengthen the body's defenses against infectious diseases. The application of CAR-T cell therapy, or chimeric antigen receptor therapy, is one significant development in this area. Engineered immune cells known as CAR-T cells express receptors unique to a particular disease. They have demonstrated notable effectiveness in treating specific forms of cancer and researchers are looking at how they may be used to treat infectious diseases. Through the successful eradication of infected cells and the targeting of viral antigens, CAR-T cell therapy has demonstrated promise against viral illnesses including HIV and hepatitis B.

In order to protect against infectious illnesses, vaccines have long been utilized. Recent developments, however, have concentrated on creating therapeutic vaccinations that may combat persistent illnesses. Therapeutic vaccinations are designed to strengthen the immune response in people who are already infected against a particular virus. For instance, scientific studies for therapeutic vaccinations for persistent viral illnesses, such HIV and hepatitis C, have yielded promising results. These vaccinations encourage the immune system to recognize and deal with the infection, which may result in long-lasting viral suppression. By inhibiting the proteins that control immune checkpoints, immune checkpoint inhibitors are a type of immunotherapeutic medications that improve the body's immunological response. They were first created to treat cancer, but they have also demonstrated potential in treating infectious disorders. These medications can counteract the immunosuppressive effects of certain infections and improve the immune response by blocking immunological checkpoints [5]. Immune checkpoint medications, for instance, have shown effective in treating chronic hepatitis B and TB infections by enhancing immune clearance of the pathogens.

Small proteins called cytokines are essential for controlling immunological responses. There is hope for the treatment of infectious illnesses thanks to recent developments in cytokine-based therapy. In HIV infection, for instance, interleukin-2 (IL-2) treatment has been investigated to boost the generation of immune cells that attack the virus. Interferon treatments have also been used to treat hepatitis B and C, boosting immune responses against the virus and lowering viral replication. The billions of bacteria that make up the human microbiome and live inside of us have a big influence on our immune systems and general health. The development of microbiome-based treatments to treat infectious illnesses has been the focus of recent study.

Conclusion

Approaches using immunotherapy to treat infectious illnesses have great potential. Innovative approaches to harness the immune system's ability to fight diseases include passive vaccination using antibodies, active immunization with vaccines, therapeutic vaccines, T-cell therapy, cytokine therapy and immune checkpoint inhibitors. Immunotherapy will need to be developed further as a therapeutic option for infectious illnesses and this will need ongoing research and development in these fields as well as clinical studies to evaluate safety and efficacy. Immunotherapeutic techniques have the potential to change the landscape of the management of infectious diseases as our understanding of the immune system advances, opening up new pathways for more effective and focused therapies.

Acknowledgement

None.

Conflict of Interest

No conflict of interest.

References

1. Ramamurthy, Dharanidharan, Trishana Nundalall, Sanele Cingo and Neelakshi Mungra, et al. "Recent advances in immunotherapies against infectious diseases." Immunother adv 1 (2021): ltaa007.

Google Scholar, Crossref, Indexed at

2. Look, Michael, Arunima Bandyopadhyay, Jeremy S. Blum and Tarek M. Fahmy. "Application of nanotechnologies for improved immune response against infectious diseases in the developing world." Adv Drug Deliv Rev 62 (2010): 378-393.

Google Scholar, Crossref, Indexed at

3. Bookstaver, Michelle L., Shannon J. Tsai, Jonathan S. Bromberg and Christopher M. Jewell. "Improving vaccine and immunotherapy design using biomaterials." Trends Immunol 39 (2018): 135-150.

Google Scholar, Crossref, Indexed at

4. Waldmann, Thomas A. "Immunotherapy: Past, present and future." Nat Med 9 (2003): 269-277.

Google Scholar, Crossref, Indexed at

5. Xu, Zhijie, Shuangshuang Zeng, Zhicheng Gong and Yuanliang Yan. "Exosome-based immunotherapy: A promising approach for cancer treatment." Mol Cancer 19 (2020): 1-16.

Google Scholar, Crossref, Indexed at